Ares Financial Consulting
ADPT icon

Ares Financial Consulting’s Adaptive Biotechnologies ADPT Stock Holding History

Ares Financial Consulting’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$20.7K Hold
715
– – 0.01% 410
2026
Q2 		$15.3K Hold
715
– – 0.01% 479
2026
Q1 		$10.3K Hold
715
– – 0.01% 538
2025
Q4 		$11.6K Buy
+715
New +$11.7K 0.01% 328

Other funds holding ADPT

Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Granite Investment Partners
Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Capricorn Fund Managers
Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Fideuram Asset Management (Ireland)
Fideuram Asset Management (Ireland) Dublin 1 $4.57B AUM 30.36% 1-Year Est. Return

Ares Financial Consulting's ADPT Position: Q3 2026 in Review

Ares Financial Consulting held its Adaptive Biotechnologies (ADPT) position steady in Q3 2026 at 715 shares worth $20.7K. The position accounts for 0.01% of the portfolio, ranked #410.

Ares Financial Consulting first reported a position in ADPT in Q4 2025 and has held it in 4 quarters since. 103 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Ares Financial Consulting held 715 shares of Adaptive Biotechnologies worth $20.7K as of Q3 2026.
  • Ares Financial Consulting left its Adaptive Biotechnologies share count unchanged in Q3 2026.
  • Adaptive Biotechnologies made up 0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #410 holding.
  • Ares Financial Consulting first reported a position in Adaptive Biotechnologies in Q4 2025 and has held it in 4 quarters since.
  • 103 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.